PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Wolters Kluwer Health, Pharma Solutions business unit, today announced the launch of Adis Reactions Pharmacovigilance Service(TM), a user-customizable alerting service that monitors current literature and provides timely notification of case reports of adverse drug reactions. Reports come in a form that facilitates easy transcription to regulatory forms. The new service greatly reduces the time required to identify relevant case reports for specific drugs and will enable pharmaceutical companies to comply with regulatory agency reporting requirements with ease and reliability.
Reactions Pharmacovigilance Service scours all of the relevant drug literature including more than 2000 journals each month and delivers alerts of adverse events as they are reported. A highly skilled and internationally respected Adis editorial staff also ensures the accuracy and reliability of the coverage.
“Reactions Pharmacovigilance Service essentially streamlines the task of monitoring the vast array of literature for case reports of adverse drug reactions,” said John Monahan, president and CEO, Wolters Kluwer Health, Pharma Solutions. “Improved efficiency not only saves customers time and money, it helps reduce the possibility of omissions or errors in their monitoring.”
The new service can be customized to meet users’ specific requirements including the ability to:
* Specify which drugs to monitor and update the list as needed * Choose between first and serious adverse reports, or all adverse reports * Select delivery frequency: daily, weekly or monthly * Request a specific electronic format to receive data: email, ASCII or XML, etc.
Customized alerts are delivered electronically and can be easily migrated to regulatory reporting forms to save time, money and facilitate compliance with FDA, EMEA, and other requirements.
Adis International is part of Wolters Kluwer Health, Pharma Solutions, one of the pre-eminent information providers to the pharmaceutical and biotechnology markets. Adis journals are among the most-cited publications in their respective fields, and provide a unique blend of original articles, authoritative reviews, profiles and drug evaluations.
Reactions Pharmacovigilance Service(TM) is available immediately as an annual subscription. Final pricing is based on geographic scope and the number of drugs being monitored. For more information, visit http://www.wkhealth.com/ or contact Mary Coleman 973-267-7210 ext. 215.
About Wolters Kluwer Health
The Wolters Kluwer Health Pharma Solutions division provides information and communications support for the pharmaceutical industry, from drug discovery and research to launch and marketing under the industry’s leading medical information brands, Adis International, IFI Claims and Lippincott Williams & Wilkins.
Wolters Kluwer Health is a unit of WoltersKluwer nv, a leading multinational publisher and information services company with annual revenues (2003) of euro 3.4 billion and employing approximately 18,750 people worldwide. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its depositary receipts of shares are quoted on the Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
For more information, visit http://www.adis.com/ and http://www.wkhealth.com/
Contact: Tom Kivett Kivett & Company Communications (212) 727-2935 tkivett@kivettandco.com
Wolters Kluwer Health, Pharma Solutions
CONTACT: Tom Kivett of Kivett & Company Communications, +1-212-727-2935,or tkivett@kivettandco.com
